ArticleBreast cancer research : BCR2015
Lobular breast cancer: molecular basis, mouse and cellular models.
Article in Breast cancer research : BCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03620643 (Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours), which is not on this map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase II Study of ROS1 Targeting With Crizotinib in Advanced E-cadherin Negative, ER Positive Lobular Breast Cancer, Diffuse Gastric Cancer, Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Histological and mutational profile of diffuse gastric cancer: current knowledge and future challenges.Molecular oncology · 2021Pooled it
- Toward targeted therapeutics for lobular breast cancer.The Journal of clinical investigation · 2026Review
- Retrospective insights: clinical characteristics and survival in 403 ILC cases from China.BMC cancer · 2025Article
- Unraveling complexity and leveraging opportunities in uncommon breast cancer subtypes.NPJ breast cancer · 2025Review
- Nomograms to predict the long-term prognosis for non-metastatic invasive lobular breast carcinoma: a population-based study.Scientific reports · 2024Article
- International survey on invasive lobular breast cancer identifies priority research questions.NPJ breast cancer · 2024Article
- Correlation between sentinel lymph node biopsy and non-sentinel lymph node metastasis in patients with cN0 breast carcinoma: comparison of invasive ductal carcinoma and invasive lobular carcinoma.World journal of surgical oncology · 2024Article
- Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.Nature communications · 2023Article
- Insights into the pleiotropic roles of ZNF703 in cancer.Heliyon · 2023Review
- Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment.Journal of experimental & clinical cancer research : CR · 2023Article
- Article
- Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.Nature cancer · 2023Article
- Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer.Journal of the National Cancer Institute · 2022Article
- VIVA1: a more invasive subclone of MDA-MB-134VI invasive lobular carcinoma cells with increased metastatic potential in xenograft models.British journal of cancer · 2022Article
- Small molecules to regulate the GH/IGF1 axis by inhibiting the growth hormone receptor synthesis.Frontiers in endocrinology · 2022Article
- Review
- Lobular Breast Cancer: Histomorphology and Different Concepts of a Special Spectrum of Tumors.Cancers · 2021Review
- Intraductal xenografts show lobular carcinoma cells rely on their own extracellular matrix and LOXL1.EMBO molecular medicine · 2021Article
- Single-Cell Transcriptomic Heterogeneity in Invasive Ductal and Lobular Breast Cancer Cells.Cancer research · 2021Article
- Asymptomatic solitary metastasis to the stomach from breast cancer: A case report.Molecular and clinical oncology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Infiltrating lobular breast cancer (ILC) is the most common special breast cancer subtype. With mutational or epigenetic inactivation of the cell adhesion molecule E-cadherin (CDH1) being confined almost exclusively to ILC, this tumor entity stands out from all other types of breast cancers. The molecular basis of ILC is linked to loss of E-cadherin, as evidenced by human CDH1 germline mutations and conditional knockout mouse models. A better understanding of ILC beyond the level of descriptive studies depends on physiologically relevant and functional tools. This review provides a detailed overview on ILC models, including well-characterized cell lines, xenograft tumors and genetically engineered mouse models. We consider advantages and limitations of these models and evaluate their representativeness for human ILC. The still incompletely defined mechanisms by which loss of E-cadherin drives malignant transformation are discussed based on recent findings in these models. Moreover, candidate genes and signaling pathways potentially involved in ILC development and progression as well as anticancer drug and endocrine resistance are highlighted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.